CIBC Bancorp USA’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
Other funds holding AKBA
CIBC Bancorp USA's AKBA Position: Q3 2026 in Review
CIBC Bancorp USA increased its Akebia Therapeutics (AKBA) stake by 79% in Q3 2026, buying an estimated $12.1K and bringing the position to 25,547 shares worth $23.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2214.
CIBC Bancorp USA first reported a position in AKBA in Q3 2025 and has held it in 4 quarters since. The position peaked at $72.8K in Q3 2025. 157 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.
- CIBC Bancorp USA held 25,547 shares of Akebia Therapeutics worth $23.5K as of Q3 2026.
- CIBC Bancorp USA bought 11,280 Akebia Therapeutics shares in Q3 2026, an estimated $12.1K.
- Akebia Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #2214 holding.
- CIBC Bancorp USA first reported a position in Akebia Therapeutics in Q3 2025 and has held it in 4 quarters since.
- CIBC Bancorp USA's Akebia Therapeutics position peaked at $72.8K in Q3 2025.
- 157 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.
Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.